Earlier today, GT Medical Technologies of Tempe, Arizona announced patients with newly diagnosed malignant tumors are now eligible to receive FDA-cleared GammaTile® Therapy in addition to patients with recurrent brain tumors.
“We are pleased to offer GammaTile Therapy to patients who are newly diagnosed with malignant brain tumors, in addition to patients with recurrent brain tumors,” said Matthew Likens, president and CEO of GT Medical Technologies. “This is a significant step forward that expands our ability to improve the lives of patients with brain tumors. Patients receiving GammaTile Therapy immediately after the removal of a brain tumor will have the peace of mind that they are accelerating their radiation treatment and targeting residual tumor cells where treatment is most needed to help prevent recurrence.”
Learn more about GT Medical Technologies, GammaTile Therapy, and the expanded indication from the U.S. Food and Drug Administration (FDA) here.